PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2514948122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Shreya R Chowdhury und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605. Hauptthemen laut MEDLINE: Membrane Proteins, Thiolester Hydrolases, Ovarian Neoplasms, Immunologic Surveillance. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Institute of General Medical Sciences (NIGMS), NCI NIH HHS, Breast Cancer Alliance (BCA).
Abstract (Originalsprache)
Immunotherapy modalities have revolutionized cancer treatment for a number of metastatic and treatment-refractory tumor types. Still, many malignancies that lack T cell infiltration and are termed immunologically “cold” fail to respond to these modalities. One approach to increase tumor immunogenicity has been to induce stimulator of interferon gene (STING) and downstream interferon signaling that is often dysregulated in cold tumors. Despite some early success of STING agonists in preclinical cancer models, these approaches have not been successful in the clinic due to poor tumor penetrance and systemic toxicities. Here, we performed a genome-wide CRISPR screen to uncover therapeutic targets to activate STING expression in human tumors. We identified the lysosomal hydrolase Palmitoyl Protein Thioesterase1 (PPT1) as a negative regulator of STING highly expressed in cold ovarian and prostate tumors. Genetic or pharmacological PPT1 suppression increased STING protein stability and its downstream activation of interferon and inflammatory cytokine signaling to enhance T cell migration. Treatment of preclinical prostate and ovarian cancer models expressing low levels of STING with the small molecule PPT1 inhibitor GNS561 enhanced STING expression and activation, leading to infiltration and activation of cytotoxic T cells that turned these tumors “hot” and reduced tumor growth, fibrosis, and dissemination without toxicity. Further analysis demonstrated that PPT1 is associated with reduced STING expression, CD8 + T cell numbers, overall survival, and immunotherapy outcomes in ovarian and prostate cancer patients. Thus, PPT1 inhibition may be a promising approach to activate STING and potentiate the effects of immunotherapy in cold tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605.
- Department of Systems Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605.
- Department of Pathology, University of Massachusetts Medical Center, Worcester, MA 01605.
- Division of Hematology-Oncology, University of Massachusetts Chan Medical School, Worcester, MA 01605.
- Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605.
- Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605.
ORCID-Profile: Lihua Julie Zhu, Michelle A Kelliher, Katherine A Fitzgerald, Marcus Ruscetti
Förderung
- HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- NCI NIH HHS
- Breast Cancer Alliance (BCA)
- NIGMS NIH HHS
- NCATS NIH HHS
- HHS | NIH | National Center for Advancing Translational Sciences (NCATS)
- DOD | MHS | CDMRP | DOD Prostate Cancer Research Program (PCRP)
Zitieren
APA
Chowdhury, S. R., Parikh, C. N., Kaur, A. N., DeMarco, K. D., Giwa, H. K., Mishra, A. K., Murphy, K. C., Zhou, L., Ma, B., Ye, T., Li, J., Liu, H., Bai, S., Johnson, C., Simin, K., Pitarresi, J. R., Zhu, L. J., Watson, E. V., Kelliher, M. A., …, & Ruscetti, M. (2025). PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2514948122
Vancouver
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, et al. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2514948122
BibTeX
@article{Chowdhury2025,
author = {Chowdhury, Shreya R and Parikh, Chaitanya N and Kaur, Arshia N and DeMarco, Kelly D and Giwa, Hadiya K and Mishra, Alok K and Murphy, Katherine C and Zhou, Lin and Ma, Boyang and Ye, Tianyi and Li, Junhui and Liu, Haibo and Bai, Shi and Johnson, Calvin and Simin, Karl and Pitarresi, Jason R and Zhu, Lihua Julie and Watson, Emma V and Kelliher, Michelle A and Green, Michael R and Fitzgerald, Katherine A and Ruscetti, Marcus},
title = {PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2514948122}
}
EUVIMED